Home » Symbiomix Therapeutics’ Bacterial Vaginosis Treatment Wins FDA Nod
Symbiomix Therapeutics’ Bacterial Vaginosis Treatment Wins FDA Nod
September 21, 2017
The FDA approved Symbiomix Therapeutics’ treatment for bacterial vaginosis.
Solosec is the first single-dose oral therapy for the indication, according to the company. The approval follows a series of studies that identified only mild to moderate adverse events.
Symbiomix will launch the drug in the first quarter of 2018.
Upcoming Events
-
21Oct